Redmile Group, LLC - Oct 28, 2021 Form 3 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
10%+ Owner
Signature
By: /s/ Jeremy Green, Managing Member of Redmile Group, LLC
Stock symbol
TRDA
Transactions as of
Oct 28, 2021
Transactions value $
$0
Form type
3
Date filed
10/28/2021, 09:01 PM
Previous filing
Oct 12, 2021
Next filing
Nov 4, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TRDA Series B Convertible Preferred Stock Oct 28, 2021 Common Stock 954K See footnote F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Series B convertible preferred stock is convertible into shares of the Issuer's common stock at any time at the holder's election, or automatically upon the closing of the Issuer's initial public offering, for no consideration and has no expiration date. This Form 3 reflects that, on October 22, 2021, the Issuer effected a one-for-7.235890014 reverse stock split of its common stock, as a result of which the conversion ratio of the Series B convertible preferred stock was proportionately adjusted.
F2 These securities are directly owned by Redmile Biopharma Investments III, L.P. (the "Fund") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Fund. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Managing Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein. This report shall not be deemed an admission that such Managing Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.